Leading expert in children's cancers appointed as a senior clinical advisor for CRUK
Cancer Research UK has announced the appointment of three senior clinical advisors to join the charity’s leadership to accelerate the progress of its ambitious research strategy.
Professor Pamela Kearns, Chair of Paediatric Oncology and Director of the Cancer Research UK Clinical Trials Unit at the School of Cancer Sciences in the University of Birmingham, is one of the three experts appointed.
She is a pioneering researcher in new types of treatment for children’s cancers and leukaemias, and in the Trials Unit she leads an international programme of large scale clinical research across all types of cancer.
Professor Kearns said: “I am excited by this amazing opportunity to work closely with Cancer Research UK. I am looking forward to working with the team to support the charity’s world-leading clinical research that will give better treatments to all children and adults diagnosed with cancer.”
Alongside Professor Kearns, two other experts – Professor Arnie Purushotham and Dr Richard Roope also join the charity on a part-time basis - to allow them to continue their existing clinical work and research.
Professor Peter Johnson, chief clinician at Cancer Research UK said: “I am delighted that we have three immensely talented clinicians joining the team at Cancer Research UK, to help us deliver on our strategy to diagnose cancer faster and treat it more effectively. We have an ambitious programme covering everything from how people can get faster access to cancer tests, how to deliver the most up to date cancer care across the UK and how to carry out the best clinical trials with all the new treatments that are coming out of our laboratory research. The clinical advisory team has the experience and skills to make sure that we can do this.”
Find out more:
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook